The molecular mechanisms, as they are currently known, of the development of these vascular lesions during hyperglycemia are complex, involving an increase in Background-Macrovascular complications of diabetes mellitus are a major risk factor for cardiovascular morbidity and mortality. Currently, studies only partially described the molecular pathophysiology of diabetes mellitus-associated effects on vasculature. However, better understanding of systemic effects is essential in unraveling key molecular events in the vascular tissue responsible for disease onset and progression. Methods and Results-Our overall aim was to get an all-encompassing view of diabetes mellitus-induced key molecular changes in the vasculature. An integrative proteomic and bioinformatics analysis of data from aortic vessels in the lowdose streptozotocin-induced diabetic mouse model (10 animals) was performed. We observed pronounced dysregulation of molecules involved in myogenesis, vascularization, hypertension, hypertrophy (associated with thickening of the aortic wall), and a substantial reduction of fatty acid storage. A novel finding is the pronounced downregulation of glycogen synthase kinase-3β (Gsk3β) and upregulation of molecules linked to the tricarboxylic acid cycle (eg, aspartate aminotransferase [Got2] and hydroxyacid-oxoacid transhydrogenase [Adhfe1]). In addition, pathways involving primary alcohols and amino acid breakdown are altered, potentially leading to ketone-body production. A number of these findings were validated immunohistochemically. Collectively, the data support the hypothesis that in this diabetic model, there is an overproduction of ketone-bodies within the vessels using an alternative tricarboxylic acid cycle-associated pathway, ultimately leading to the development of atherosclerosis. Conclusions-Streptozotocin-induced diabetes mellitus in animals leads to a reduction of fatty acid biosynthesis and an upregulation of an alternative ketone-body formation pathway. This working hypothesis could form the basis for the development of novel therapeutic intervention and disease management approaches. (Circ Cardiovasc Genet. 2014;7:161-170.)
D iabetes mellitus is characterized by hyperglycemia and recognized as one of the major contributors to health problems worldwide. 1 One of the greatest contributors to morbidity and mortality in diabetics is a 2-to 8-fold increased risk of developing vascular disease. 2 Hyperglycemia affects both macrovascular (coronary artery disease, peripheral arterial disease, and stroke) and microvascular complications (diabetic nephropathy, neuropathy, and retinopathy). Affected vessels display major histological changes, 3 including increased intima-media thickness, in part as a result of increased vascular smooth muscle cell proliferation, adhesion, and migration, 4 as well as elevated extracellular matrix, in particular collagen, deposition. The overproduction of elevated extracellular matrix proteins and increased cross-linking of collagen can lead to aortic fibrosis, a major component in diabetic hyperglycemia. 5 proinflammatory signals (eg, activation of nuclear factor-κB, adhesion molecules, tumor necrosis factor-α, interleukin-1β and interleukin-6). 6 Downstream of these proinflammatory factors extracellular signal-regulated protein kinase-1, c-Jun NH2-terminal protein kinase-1 and -2, and p38 are activated. 7 A further hallmark in the development of diabetic vascular lesions is the production of reactive oxygen species, resulting in inactivation of nitric oxide and appearance of advanced glycation end-products, further aggravating vascular tissue damage. 8 Several proteins have been proposed as targets for hyperglycemic changes in the vascular smooth muscle cells, including protein kinase C and the inositol trisphosphate-and ryanodine receptors. 9 Inositol 1,4,5-trisphosphate-sensitive and ryanodine-sensitive stores are the major contributors to Ca 2+ homeostasis in vascular smooth muscle cell. 10 The complexity of the vascular response to diabetes mellitus is further exemplified by a recent proteomic study, showing that the most prominent diabetes mellitus-associated changes were in proteins linked to oxidative stress and the structure/ function of myofibrils and microfilaments, with decreased levels of glycolytic enzymes and mitochondrial electron transport system complex components. 11 Further studies suggest an association of mitochondrial dysfunction, persistent hyperglycemia-induced mitochondrial oxidative stress, 12 and decreased activity of several antioxidant enzymes in diabetic hyperglycemia in both rats and humans. 13 This existing, yet disparate, molecular evidence on diabetes mellitus-associated effects on vasculature indicates a need for a holistic approach, interlinking the findings. Such detailed analysis and further integration of data in a systems medicine approach is proposed to provide a better understanding of diabetes mellitus-associated vascular changes and to open new avenues toward improved interventional therapies.
A well-established and accepted model of hyperglycemia is streptozotocin-induced diabetes mellitus in animals, 14 which displays many of the hallmarks of diabetes mellitus-evoked vascular pathology. In the current study, we used proteomic profiling to investigate aortic vessels from streptozotocin-induced diabetic mice and controls, followed by functional bioinformatics analyses to investigate deregulated processes on a molecular level. Our analysis recapitulates and further links many of the known molecular hallmarks of diabetic arteriopathy at the pathway level and in addition suggests diabetes mellitus-induced production of ketone-bodies in the vessels.
Methods

Materials
All chemicals were obtained from Sigma-Aldrich (Gillingham, UK) unless stated otherwise.
Animal Model
Seven-week-old C57BL/6 male mice were obtained from Charles River (Sulzfeld, Germany) and housed at the Saarland University animal facility. All animals had free access to a standard laboratory diet with free access to water. All procedures were performed according to Federation for Laboratory Animal Science Associations (FELASA) guidelines and were approved by local authorities. Experimental diabetes mellitus was induced in 8-week-old weight-matched mice by multiple low doses of streptozotocin. Mice were injected intraperitoneally with either 50 mg/kg body weight streptozotocin (Sigma-Aldrich) in 50 mmol/L sodium citrate (pH 4.5) or sodium citrate buffer for 5 consecutive days. After 20 weeks of hyperglycemia, the animals were euthanized. Thoracic and abdominal aortas were removed and frozen in liquid nitrogen and stored at -80°C until sample preparation for mass spectrometry (MS) or carefully frozen in liquid nitrogen vapor for immunohistochemistry.
Blood Glucose Measurements
Blood glucose was measured 20 days after the first streptozotocin injection and monthly thereafter (Glucometer Elite System; Bayer, Leverkusen, Germany). Animals with glucose levels >12 mmol/L after 4 hours of fasting were considered diabetic. Animals that were not hyperglycaemic within 20 days after the first streptozotocin injection were excluded. Mice received no insulin. Ketonuria did not occur.
Sample Preparation and Mass Spectrometry Analysis
Tissue samples were weighed and extracted using the Filter Aided Sample Preparation method 15 (see Methods in the Data Supplement for a detailed description) and analyzed on an Orbitrap-Velos FTMS (Thermo-Finnigan, Bremen, Germany) as described, 16 operated in a data-dependent mode (top 40) to switch between MS and MS/ MS acquisition, using collision-induced dissociation. Data files were searched against the mouse IPI database using SEQUEST, integrated in Proteome Discoverer (Thermo Fisher Scientific, Hemel, UK), setting carbamidomethylation as fixed and phosphorylation, methionine, and proline oxidation as variable modifications. Mass error windows of 10 ppm and 0.8 Da were allowed for MS and MS/MS, respectively. Peptide data were extracted using high peptide confidence and top 1 peptide rank filters. Statistical P value analysis of the normalized precursor ion peak areas was performed using the Wilcoxon and Mann-Whitney test. Source MS and MS/MS data files are available at PeptideAtlas (http:// www.peptideatlas.org/) with the identifier PASS00380.
Bioinformatics Analysis
Analysis was performed on proteins with P values ≤0.05 (72 proteins). Functional association was done using the controlled vocabulary of the Proteomics Analysis DataBase protein classification system (PADB.org). Gene Ontology (GO) keyword-cluster analysis was performed using the CluGO CytoScape plug-in (www.cytoscape.org). 17 Interactome analysis was performed using the Michigan Molecular Interactor plug-in (mimi.ncibi.org). 18 The condensed protein interaction analysis was conducted by searching for direct associations, followed by stepwise expansion to tie in other molecular clusters. This analysis uncovers novel signaling pathways because molecules with similar cellular involvement tend to cluster together through physical interactions, such as those found in molecular machines. 19 Metabolic pathway analysis was done with PathVisio (www. pathvisio.org). 20 Additional enzymatic reactions were retrieved from BRaunschweig ENzyme Database (BRENDA) (http://www.brendaenzymes.org/). The disease analysis is based on known or inferred genetic disorders associated with mutations of specific genes as stored in the Online Inheritance in Man (OMIM) database using the human orthologous genes, respectively. The successive pathway analysis was done using the CytoScape iRefScape plug-in (irefindex.uio.no/ wiki/iRefScape_1.0) 21 by gene-name mapping and OMIM accessionnumber extraction of the resulting networks.
Histology and Immunohistochemistry
Cryosections were fixed for 10 minutes in acetone, followed by antigen retrieval using 0.1 mol/L HCl/KCl for 10 minutes. After blocking in PBS containing 10% fetal calf serum (FCS), sections were incubated with primary antibodies overnight (myosin [Sigma], smooth muscle actin [Santa Cruz], Gsk3β, fatty acid synthase [Fasn; Santa Cruz], pyruvate dehydrogenase kinase isoform 4 [Pdk4; Abcam], mitochondrial Got2 [Abcam], mitochondrial Adhfe1 [Proteintech]), followed by incubation with Cy3 conjugated secondary antibodies (Jackson Laboratories). Images (×200 and ×400 magnification) were captured using a Zeiss LSM510 Meta confocal microscope and Zeiss LSM software (Zeiss, Germany). Medial thickness was measured using LSM Image software (Zeiss, Germany) of blinded cryosections (n=3). Four random measurements were collected per section, and 3 sections were analyzed per animal. Oil red O staining was performed on 10-μm cryosections fixed in 10% formalin. After incubation in propylene glycol, sections were incubated in Oil red O solution at 60°C and subsequently differentiated in 85% propylene glycol. After mounting, images were captured using an Axiophot microscope (Zeiss) and an Axiocam camera (Zeiss) using brightfield setting. Histograms and quantification of fluorescence signal for immunohistochemistry stainings were generated by splitting the red-green-blue (RGB) color channels and calculating the ratio between the red channel (probe) and the blue (nuclear stain) for each individual panel using ImageJ. The Oil red O histogram used a calculation of the red versus the sum of green and blue channels. This was done using blinded sections, and 3 random measurements were taken per section. Statistical significance was calculated using unpaired t test (see Methods in the Data Supplement for a detailed description).
Results
Animal Model
Mice became diabetic within 2 weeks after streptozotocin injection, and hyperglycemia persisted throughout the 19-week experimental period. Average blood glucose levels were 395 mg/dL in diabetic mice. At the end of week 19, bodyweight gain was 20% in diabetic and 28% in control animals ( Table 1 ). Values for the medial thickness were significantly higher for diabetic aortas (28 μm) than for control aortas (19 μm), indicating thickening of the vascular wall in diabetic mice ( Table 1 ; Figure 1 ). There was no significant difference in total protein content between groups of diabetic and control aortas.
Mass Spectrometry Analysis and Data Acquisition
Proteins from 5 aortic control and 5 aortic diabetic samples were analyzed by liquid chromatography tandem mass spectrometry. A total of 442 725 MS/MS-spectra were matched to 9257 peptides, corresponding to 2205 unique proteins ( Table I in the Data Supplement). The protein identification false-discovery rate was 0.38%. A total number of 996 proteins were found in both diabetic and control samples. A total number of 600 proteins could only be observed in control samples and 609 only in aortas from diabetic mice. A total of 72 entries, of which 18 were only found in 1 group, were selected as likely differing in distribution, based on a nominal P value <0.05 (Tables I and II . Adjustment of P values using Benjamini-Hochberg correction for multiple testing showed a lack of statistical power, and none of the individual peptides achieved statistical significance after adjustment for multiple testing using the Benjamini-Hochberg correction. However, comprehensive pathway mapping is not dependent on individual statistical significances.
Bioinformatics Data Analysis Workflow
Proteins exhibiting clear differences in distributions between treated and untreated samples (P<0.05; Table II in the Data Supplement) were used as input data in the different bioinformatics approaches, including GO, interactome (Michigan Molecular Interactor), or metabolic pathway (PathVisio) analysis, as well as literature and OMIM database mining, aiming to capture the maximum available information and identify differentially expressed pathways and key molecules in aortic vessels of diabetic mice. Figure 2 depicts the overall workflow, and Table 2 summarizes the results of the individually performed bioinformatics approaches. Brief explanations on the applied in silico bioinformatics analyses are provided in the following sections.
GO Analysis, Interactome Mapping, and Metabolic Pathways
GO analysis is based on statistical testing of associated keywords (retrieved from the GO database) for each molecule. The interactome cluster analysis provides information on group clustering and physical linkage. We also used metabolic pathway analysis by protein mapping to preassembled metabolic and signaling pathways. Significant pathways were identified after statistical testing of molecules contained in each individual pathway map according to the respective pathways analysis software. The results indicate a clear upregulation of myofibrillar/muscle contraction pathways involved in muscle function and a downregulation of cell cycle pathways (with key proteins Gsk3β and 14-3-3), inhibitors involved in the response to stimulus (Serpins), and the GO-group cluster of enzymatic processes involved in pentose-phosphate shunt (transaldolase [Taldo1], Tkt, decarboxylating 6-phosphogluconate dehydrogenase [Pgd]) and fatty acid (acetyl-CoA carboxylase 1 [Acaca], Fasn, estradiol 17-β-dehydrogenase 12[Hsd17b12]) pathways (Figures I and IIA, IIB). We also observed a marked upregulation of proteins associated with muscle metabolic turnover (glycolysis) along with the pronounced downregulation of fatty acid metabolism ( Figure 3 ). In addition, an alternative ketone-body formation pathway, linked to tricarboxylic acid (TCA) cycle metabolites, seems to be upregulated.
OMIM Disease Clusters and Literature/Text Mining
To explore whether known human diseases, which might be associated with diabetic conditions, map to the statistically significant proteins observed in this study, we examined associations of molecules to human conditions using iRefScape and data mining of the OMIM database ( Table III in Table 3 . This analysis showed that proteins involved in fatty acid storage, glucose metabolism, and apoptosis were all downregulated, whereas molecules taking part in myogenesis and vascularization, as well as being linked to hypertension and hypertrophy, were substantially upregulated.
Combinatorial Analysis and Interlinking-Affected Pathways
Pathway assembly was performed by interlinking the findings and generating a global denovo pathway assembly using Path-Visio. Interlinking of the aforementioned analyses revealed a general downregulation, from glucose to the end-products of the fatty acid biosynthesis pathway, an upregulation of the classical muscle-based energy metabolism from glucagon to lactate involving the metabolic pathway controlling enzyme Pdk4, a compensatory (upregulated) pathway from primary alcohols such as ethanol to acetyl-CoA, and altered alternative bypass-mechanisms of the TCA cycle ( Figure 3 ). This collection of enzymes associated with the use of TCA cycle metabolites in particular can form a pathway that directly leads to the formation of ketone-bodies through incorporation of L-glutamate via Got1/2, mitochondrial L-2-hydroxyglutarate dehydrogenase, and Adhfe1. The first 2 enzymes were found to be upregulated in our proteomic analysis, whereas Adhfe1 was not detected but is predicted to produce the end-product. The same end-product is also formed by breakdown and (Table 3 ; Table IV in the Data Supplement) , resulting in a unified pathway model (Figure 3) , of which key components were validated by immunohistochemistry ( Figure 4) . deamination of amino acids, also implied to be upregulated in the disease pathway model. Suggested signaling pathways modulated in streptozotocin-treated diabetic animals include tumor necrosis factor-α, nuclear factor-κB, and pathways downstream of insulin-signaling involving Gsk3β, protein kinase A, and calcium/calmodulin-dependent protein kinase type II ( Figure III in the Data Supplement), in all cases being downregulated in the diabetic versus control animals.
Validation of Findings
We subsequently sought to verify the most prominent findings using immunohistochemistry. Our criteria for target selection for further validation included the placement of the candidate proteins in apparently disconnected molecular pathways, in combination to reagent (antibodies) availability. Specifically, prototypic proteins, actin, GSK3b, myosin, and Fasn were chosen. On the basis of this pathway analysis, we extended the validation to also include Pdk4, Got2, and Adhfe1. As shown in Figure 4 , immunohistochemistry confirmed the changes observed in the proteomic analysis and suggested after the bioinformatics analysis. Histograms for each staining are shown ( Figure 4 ) as indicators of protein expression changes, nevertheless not reflecting absolute values. Smooth muscle actin staining revealed that streptozotocin-treated animals developed increased medial thickness, although no increase in the level of smooth muscle actin was observed (Figure 1C) . Interestingly, the smooth muscle of diabetic animals displayed increased myosin staining ( Figure 4A ), confirming the observed upregulation of proteins involved in myogenesis and muscular functions. To substantiate the link between diabetes mellitus and hypertension, we examined the expression levels of Gsk3β ( Figure 4B ) and could demonstrate a downregulation of this molecule in aortas of streptozotocin-treated animals. To investigate the proposed reduction in fatty acid biosynthesis pathways, the expression of Fasn ( Figure 4C ) was also examined. Staining revealed a significant reduction of the protein in diabetic animals. Diabetic animals also revealed reduced Oil red O staining, indicating a general reduction in fat deposits in the tissue ( Figure 4D ). This is most likely because of a reduction in the fatty acid synthesis, as indicated by the reduced Fasn staining and proteomic analysis and because of the increased muscularization of the tissues and consequent shift in metabolism. Pathway analysis indicated an increase of the glycolytic pathway, in part, commonly associated with muscle metabolism, leading to increased lactate, pyruvate, and acetyl-CoA accumulation, which is controlled by Pdk4 by inhibiting the pyruvate to acetyl-CoA conversion. An increase in this kinase, as suggested by our proteomic analysis, was confirmed by immunohistochemistry ( Figure 4E ) and could be a protective mechanism of vascular smooth muscle cells under hypoxic conditions to avoid the accidental activation of the oxygen-dependent TCA cycle. Metabolic pathway analysis also strongly indicated a direct link to ketone-body formation using an unconventional alternative pathway linked to the TCA cycle. To substantiate this, we performed staining for Got2 as the branching point from the TCA cycle and could clearly show an increase of this molecule in aortas of streptozotocintreated animals, thereby confirming proteomic data for this molecule ( Figure 4F ). The ultimate step in this ketone-body formation process involves the iron-dependent alcohol dehydrogenase Adhfe1. Although we could not detect this protein in the proteomic analysis, we found it to be upregulated in the streptozotocin-treated animals' aortas by immunohistochemistry, in line with our predictions ( Figure 4G ).
Discussion
Diabetes mellitus-associated complications affecting the macro-and microvasculature are major causes of mortality and morbidity, but the underlying mechanisms remain relatively poorly understood. 22 Analysis of the aortic proteome could provide valuable insights in the development of diabetes mellitus-associated macrovascular pathologies. 23 Streptozotocin-induced diabetes mellitus in mice is a well-established model to investigate processes leading to diabetic conditions, such as cardiomyopathy, nephropathy, arteriopathy, stroke, and ultimately organ failure. 24 Inspired by the data from Didangelos et al, 25 we initiated a comprehensive proteomic study of diabetic aortas in the streptozotocin model in comparison with untreated controls coupled with extensive bioinformatics and systems The output of the various analysis approaches, using the 72 statistically significant differentially expressed proteins, is shown. GO indicates gene ontology; NF-κB, nuclear factor-κB; OMIM, Online Mendelian Inheritance in Man; and TNF, tumor necrosis factor.
Figure 3.
Alternative metabolic pathway analysis in the formation of ketone-bodies. Proteins involved in metabolic pathways were mapped onto known pathways, including glycolysis, fatty acid pathways, pyruvate/lactate pathways, tricarboxylic acid cycle bypass pathway, amino acid breakdown, and ketone-body production. Green, downregulated; red, upregulated. Proteins that were validated by immunohistochemistry are highlighted (blue frame). biology analysis. We observed substantial changes in 72 (P<0.05) of 2205 detected nonredundant aortic proteins. A full molecule-by-molecule discussion of the differentially expressed proteins found in this study and their potential or known involvement in diabetic conditions is provided in Table IV in the Data Supplement. Some of these proteins were previously reported as diabetes mellitus-associated (18 molecules), but the majority (54 molecules) was not described in the context of diabetes mellitus.
A characteristic example of the former category is the fatty acid-binding protein 3 (Fabp3), showing elevated expression levels in diabetic aortas. Fabp3 is involved in fatty acid transport, and its overexpression was reported to induce apoptosis. 26 In prediabetic, impaired glucose-tolerant conditions, elevated levels of Fabp3, and an associated thickening of the arterial intima-media have been shown, 27 in accordance with our results. Because both muscle cells and adipocytes express Fabp3, 28 streptozotocin diabetic vessels have increased intima-media thickening and reduced Oil red O staining in the adventitia; we consider it highly likely that increased Fabp3 expression levels are in vascular smooth muscle cells. This may also apply to fatty acid-binding protein 4 (Fabp4), downregulated in our study, which was described to impair the insulin-dependent nitric oxide pathway in vascular endothelial cells. 29 Elevated Fabp4 serum levels have been shown to be associated with diabetes mellitus, diabetic nephropathy, stroke, and vascular inflammation. 30 Thus, the observed downregulation in aortic tissue might be a consequence of active exocytosis or a cellular protective event.
In line with existing knowledge supporting a major role of oxidative stress in diabetic conditions, we observed increased levels of the well-characterized oxidative stress protein Aldose reductase (Akr1b1). This molecule is a key enzyme in diabetes mellitus-induced oxidative stress, 31 and its overexpression has been shown to result in higher susceptibility to myocardial ischemic injury. 32 Nuclear factor-κB induces Akr1b1 expression under high glucose conditions, 33 and recent findings suggest that it is also the primary prostaglandin F synthase and possibly a modulator of other signaling molecules. 34 A substantial number of modulated proteins observed in this study (Table 3) has been reported previously to be linked to hypertrophy and hypertension, shown to coexist in diabetes mellitus 35 and also reported to occur in streptozotocin-treated animals. 36 Deletion of Gsk3β in mice was shown to lead to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. 37 We observed a pronounced downregulation of this protein by both our proteomic screen and immunohistochemistry of the diabetic aortas, and our data implicate for the first time that reduced Gsk3β-levels occur in aortas in streptozotocin-induced diabetic conditions. If confirmed in humans, this finding may consequently lead to a novel-targeted approach in disease management and diagnosis of diabetic conditions. Indeed, Gsk3β was selected as a potential therapeutic target in human type 2 diabetes mellitus, 38 based on observed increased expression and activation of this protein in human muscle tissue 39 and mouse models. 40 In animal carotid arteries, vascular lesions lead to an upregulation of glucose metabolism in vascular smooth muscle cells and promote an antiapoptotic pathway that is associated with the inactivation of Gsk3β. 41 Our observed downregulation could, therefore, be a direct effect of an apparent upregulation of glycolytic enzymes.
On the basis of the systems biology approach in this study, we were able to determine potential correlations of the different pathways and indicate that many pathways involved Statistically significant proteins (n=72; P<0.05) were analyzed based on their potential involvement in diabetes mellitus or diabetes mellitus-associated pathologies based on literature searches, OMIM annotations, or KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways, and grouped accordingly. The cellular location was derived from the UniProt database, and some proteins are listed as both cytoplasmic and nuclear. The average fold changes were calculated by omitting any entries that were unique to 1 group (streptozotocin treated or control).
in diabetes mellitus show substantial overlap. Of the most relevant findings, metabolic pathway analysis suggests that ketone-body formation is upregulated through an alternative pathway. Starvation and diabetes mellitus induce an upregulation of glucocorticoid signaling, resulting in elevated levels of Pdk4, 42 which we also observed in our study. Pdk4 is the key mediator in preventing the conversion of pyruvate to acetyl-CoA by inhibiting pyruvate dehydrogenase complex C. In the liver, this inhibition enables ketone-body synthesis from fatty acids and ketogenic amino acids rather than 3 carbon compounds, which are then available for gluconeogenesis in the liver to maintain blood glucose levels. 43 Our data indicate that activation of the glycolytic mechanism and co-occurring inhibition of the pyruvate to acetyl-CoA metabolic step may lead to an activation of an alternative TCA-bypass mechanism involving Got2, oxaloacetate, and L-glutamate, leading to a production of 2-oxoglutarate. This mitochondrial step may be supported by the observed upregulation of the glutamate/ aspartate exchanger aspartate glutamate carrier 1 (Slc25a12), which imports glutamate in exchange for aspartate. Got2, a key enzyme for endogenous sulfurdioxide production, has been implicated in isoproterenol-induced myocardial injury, 44 but its role in diabetes mellitus is unknown. The next molecule in this alternative pathway is L-2-hydroxyglutarate dehydrogenase, known to produce 2-hydroxyglutarate 45 and upregulated in our proteomic screen; however, no information exists on whether it is involved in streptozotocin-induced diabetes mellitus. The ultimate enzyme in this novel pathway, Adhfe1, which forms β-hydroxybutyrate, and which we postulate to be part of this pathway, could be shown to be upregulated by immunohistochemistry. Adhfe1 is expressed in adipose tissue, 46 but involvement in diabetic conditions has not been described. This, combined with an elevated breakdown of amino acids, might lead to the localized overproduction of ketone-bodies. Uncontrolled production of ketone-bodies leads to ketosis and ultimately ketoacidosis, 47 1 of the hallmarks of type I diabetes mellitus. Our results suggest that this mechanism occurs locally within the macrovasculature and is not a product of the classical ketone-body formation by β-oxidation because all molecules involved in this pathway that we could detect are downregulated ( Figure III , inset in the Data Supplement). The overall contribution of locally produced ketone-bodies to the total pool found in blood at this stage is unclear; however, it is estimated to have a minimal effect on distant tissues in subjects with diabetes.
In summary, we have identified several proteins and pathways implicated in the pathogenesis of diabetic arteriopathy. Key findings include decreased glycolysis and fatty acid metabolism, a pronounced increase in vascularization, oxidative stress-response proteins, apoptosis modulators, and molecules involved in hypertrophy and hypertension. Strong evidence supporting production of ketone-bodies locally within the vessels is provided, and key molecules involved in this process are highlighted. However, limitations, such as transferability of results from the animal model to human disease, suboptimal statistical evidence because of relatively low sample numbers, and lack of corroborative metabolic information, still persist. Nevertheless, confirmatory evidence was collected to justify further validation studies in humans. In Figure 4 . Immunohistochemical analysis of diabetic mouse aorta. A, Aorta from streptozotocin (STZ)-treated animals display increased myosin staining (red) in the media the of the vessel wall, (B) reduced glycogen synthase kinase-3β (Gsk3β) staining (red) in adventitia of diabetic mice, (C) reduced fatty acid synthase (Fasn) staining (red) in adventitia of treated animals, (D) reduced fat deposition in adventitia of treated mice as shown by Oil red O staining, (E) increased pyruvate dehydrogenase kinase isoform 4 (Pdk4) staining (red), (F) increased aspartate aminotransferase (Got2) staining (red), and (G) increased hydroxyacid-oxoacid transhydrogenase (Adhfe1) staining (red). DAPI (4',6-diamidino-2-phenylindole) (blue) is used to stain nuclei. Size bar shown in the lower corner of A to G (left) is 50 μm. Histograms show ratios between red and blue channels of the individual panels apart from Oil red O, which is the ratio between red and blue+green channels. The mean values of 9 measurements each (originating from 3 independent animals per category), including the SEM, the Student P value, and the calculated fold changes from the immunohistochemistry analysis, as well as the MS results shown underneath. a Averaged across all myosin isoforms observed, b only found in control samples, c only found in STZ-treated samples, and d not found by mass spectrometry. addition, given the importance of post-translational modifications in protein function, their investigation in relation to phenotype development is warranted. Such targeted approaches investigating post-translational modifications and activities of selected proteins, as well as providing local measurements of metabolites through advanced metabolomics techniques, should now be applied. Our preliminary in silico comparison of the observed molecular alterations in the mouse model versus molecular alterations in human diseases presented herein strongly supports that such endeavors are justified.
Collectively, this study contributes a significant number of proteomics data to the current knowledge on vascular tissue and diabetes mellitus-related molecular changes. Even more, analyzing the data in depth using a combination of bioinformatics tools reveals a multitude of modifications in many metabolic and proteomic pathways that would normally require a range of investigative techniques to be identified. A substantial proportion of the common chronic diseases, such as diabetes mellitus and its cardiovascular, renal, and retinal complications, coronary artery disease, hypertension, stroke, and vascular dementia, is all in part caused by underlying arterial diseases. 48 However, their commonalities and identification of causative agents remain to be investigated in many cases. The presented in-depth analysis of alterations occurring locally (eg, at the vessels), in this case induced by diabetes mellitus, is highly relevant and easily adaptable to the study of blood vessels from additional disease states opening thus new avenues of research toward finding common molecular denominators of multiorigin arterial diseases.
